Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan vs Dexlansoprazole in GERD
NCT06778395Phase 4Completed
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of vonoprazan in gastroesophageal reflux disease (GERD) (2 arms). Primary endpoint: Symptom relief assessed by the GERD-Q score at 8 weeks. Started Oct 2024; status: completed.
02
Drugs
vonoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06778395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06778395.